Accurate and consistent variant classification is imperative for incorporation of rapidly developing sequencing technologies into genomic medicine for improved patient care. An essential requirement for achieving standardized and reliable variant interpretation is data sharing, facilitated
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For the ClinGen/ClinVar Special Issue variants in Mendelian disease, including FH. Here, we present the concerted efforts made by the Clinical Genome Resource, through the FH Variant Curation Expert Panel and global FH community, to increase submission of FH-associated variants into ClinVar. Variant-level data was categorized by submitter, variant characteristics, classification method, and available supporting data.
To further reform interpretation of FH-associated variants, areas for improvement in variant submissions were identified; these include a need for more detailed submissions and submission of supporting variant-level data, both retrospectively and prospectively. Collaborating to provide thorough, reliable evidence-based variant interpretation will ultimately improve the care of FH patients.
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INTRODUCTION
Familial hypercholesterolemia (FH) is an autosomal codominant disorder, characterized by elevated low-density lipoprotein (LDL) cholesterol (LDL-C) levels causing premature atherosclerotic cardiovascular disease when left untreated. FH affects an estimated one in 250 individuals worldwide (Akioyamen et al., 2017) , and is considered to be the most frequent monogenic disorder encountered in clinical practice.
Since the 1970s, a vast number of potentially pathogenic DNA variants have been identified in FH patients, primarily within LDLR (the gene encoding the LDL receptor), and more recently in other genes involved in LDL metabolism: APOB and PCSK9 (genes encoding apolipoprotein B and proprotein convertase subtilisin/kexin type 9, respectively). Characterizing the genetic etiology of FH has improved our understanding of disease pathophysiology and associated risks, in addition to improving patient management (Defesche et al., 2017; Goldstein & Brown, 2009 ).
Interpreting the clinical significance of genetic variants is challenging (Bland et al., 2018) , and has direct implications for diagnosis and family-based "cascade" screening. While improvements in variant interpretation may aid in the implementation of genetic testing into more routine FH clinical care, this is enhanced when there is information on variants from multiple independent sources that can be shared among laboratories. This data-sharing culture is not new among the FH field; for years the Leiden Open Source Variation Database (LOVD) has served as a publicly available FH-variant repository, hosting 1,707 unique LDLR variants as of 2016 (Leigh et al., 2017) . However, ClinVar, an NCBI-funded resource, has since emerged as the primary centralized database for archiving clinically relevant variants for many Mendelian diseases, including FH. ClinVar facilitates a comprehensive approach to both the consolidation and presentation of patient and molecular data, and includes a multitude of interconnected resources to aid in improving variant interpretation (Harrison et al., 2016 
METHODS

ClinGen FH Variant Curation Expert Panel
The ClinGen FH Variant Curation Expert Panel (FH VC-EP) is composed of >20 members (Supporting Information Table S1 ). Members were selected on the basis of achieving a balanced representation of expert clinicians, clinical laboratory diagnosticians, researchers, and genomic medicine specialists. An emphasis was also placed on global representation, with members from the United States, Brazil, United Kingdom, the Netherlands, France, Portugal, Czech Republic, Spain, Israel, Australia, and Canada. The FH VC-EP is a part of the ClinGen Cardiovascular Clinical Domain Working Group. 
Variant submission to ClinVar
ClinVar variant analysis
Following submission efforts, ClinVar Miner (https://clinvarminer.
genetics.utah.edu/) was used to extract variant-level data from the ClinVar database for LDLR, APOB, and PCSK9. Variants that did not have a submitted disease association of FH or accepted alternative term were removed manually, specifically: "familial hypobetalipoproteinemia" (n = 221), "hypercholesterolemia, autosomal dominant, type B; hypobetalipoproteinemia, familial, 1" (n = 156; entry of two opposing conditions per single individual), "LDL-C level quantitative trait locus 1" (n = 3), "hypocholesterolemia" (n = 2), "hypobetalipoproteinemia, familial, 1" (n = 2), "early-onset coronary artery disease (CAD)" (n = 2; removed as other dyslipidemias/morbidities can lead to CAD), "hypobetalipoproteinemia" (n = 1), "C0950123: inborn genetic diseases" (n = 1), "not specified" (n = 191), and "not provided"
(n = 164). Variant consequences were determined manually from DNA and protein-level variant information and confirmed using the Mutalyzer Name Checker batch tool v.2.0.28 (Leiden University Medical Center, Leiden, the Netherlands; https://mutalyzer.nl/). 
RESULTS
Global ClinVar submission
FH-associated variant characteristics
Unique FH-associated variants present on ClinVar are categorized by type for LDLR, APOB, and PCSK9 in Table 3 and shown by location across all exons in Figure 1 . Missense variants are the most prevalent unique variant type in each of the three genes, followed by frameshift variants in LDLR, and synonymous variants in both APOB and PCSK9.
In LDLR 18% of all unique variants are located in exon 4, in APOB 41% are in exon 26 and 15% in exon 29, and in PCSK9 19% are in the 3'UTR (untranslated region). Figure 2 illustrates the relative proportions of variant classifications for each variant type.
Variants submitted to ClinVar range from benign to pathogenic or can be submitted without an assertion; with the exception of 198 FH-associated variant submissions, submitting centers provided a pathogenicity classification for their variants, found summarized by gene in Table 4 . Unique variants are categorized by classification in (Table 6 ).
Variant classification methods
Variant-level data
Some variants (n = 1,972 unique; 3,435 submissions) were submitted with some kind of supporting variant-level data. This included information on patient clinical features, if there was family history of disease, the number of variant alleles or number of families with the variant identified, number of families with observed segregation, if it was an incidental finding and note of any related functional studies published (Table 7) . However, information of co-segregation was only submitted to ClinVar for eight variants, and phenotype data was only submitted for 490 unique variants (in 1,043 total submissions). Functional studies were reported for 334 unique variants (437 submissions), the majority submitted as literature review by a single group. Because a loss-of-function in LDLR is a known disease mechanism of This effort has also revealed that many different variant classification methods are being used, which is problematic since non-standardization can lead to different interpretation of identical variants. Indeed, we saw 379 variants (∼15% of variants in each gene) with conflicting classifications. Use of ACMG/AMP guidelines aims to achieve greater standardization and consistency in variant interpretation (Richards et al., 2015) . As we saw here, many FH research and diagnostic groups have adopted this new standard. However, the ACMG/AMP guidelines were designed to be generalizable to all Mendelian disorders, and ambiguities leave potential for differences in the application of various criteria among users, yielding inconsistent classifications. For instance, 114 unique variants have conflicting classifications despite all submitters having cited the ACMG/AMP guidelines.
TA B L E 2 Centers that submitted FH-associated variants to ClinVar
Beyond a degree of inherent subjectivity, the current ACMG/AMP guidelines do not adequately address FH. In a separate study, ACMG/AMP classification of a large subset of FH-associated variants resulted in a large proportion of VUS (42% in LDLR, as well as 90% in APOB and 92% in PCSK9; Chora et al., 2017) . Cases of misclassifications when compared against known pathogenic/benign variants were also found. One of ClinGen's key goals is the standardization of gene/disease-specific adjustments to the ACMG/AMP guidelines to address these issues, and to use these specified guidelines to provide a high level of confidence in ClinVar variant classifications.
Following a rigorous step-wise process that includes completion of a pilot study and development of a sustained variant curation and discrepancy resolution plan, the FH VC-EP will submit an application for In-frame indels: smaller than one exon; intronic: variants after +/−15 nucleotides (nts) in the intron; splicing: variants known to affect splicing + variants within +/−15 nts in the intron; CNVs: one whole exon or more; cis variants (single submission of two variants on same allele) include: three double missense, one in-frame indel + frameshift, one in-frame indel + missense. CNV, copy number variation; indel, insertion or deletion; UTR, untranslated region. Efforts are underway to encourage outstanding centers to submit their variants, and it is imperative this is achieved prior to the reclassification of all variants using FH-specified ACMG/AMP criteria to ensure diverse representation is accounted for in the specification of these criteria. Further, FH-associated variants are likely being identified on an exponential scale as NGS panels are becoming increasingly implemented in routine FH diagnosis , a trend sure to continue as sequencing costs continue to plummet and awareness of FH broadens. Thus, real-time submission of variant data must be a focus for all centers, due to the potential implications this data may have on ACMG/AMP-algorithm-derived variant classifications.
TA B L E 4
CONCLUSION
Efforts of data sharing and reliable variant interpretation are extremely important to improve the care of FH patients. Since FH is so prominent in the population, and as educational efforts continue, more health care/family physicians can be expected to order genetic 
